Updated:
Larimar Therapeutics
Larimar Therapeutics, led by CEO Carole Ben-Maimon, develops nomlabofusp for Friedreich's ataxia in Bala Cynwyd, PA.
Larimar Therapeutics
Larimar Therapeutics registered in 2005 under the name Zafgen, originally focused on obesity and metabolic disorders. The current entity emerged from a 2020 merger with Chondrial Therapeutics, a privately held biotech founded to develop protein-replacement therapies for rare mitochondrial diseases. Carole Ben-Maimon, a former generics executive who previously ran global pharmaceuticals at Impax Laboratories, assumed the CEO role following the merger and reshaped the company's mission around a single lead program: nomlabofusp, previously known as CTI-1601. The firm advances nomlabofusp as a subcutaneously administered fusion protein that shuttles human frataxin across cell membranes and into mitochondria. Larimar's strategy is narrowly focused on one indication — Friedreich's ataxia — with a Phase 2 trial readout serving as the primary value catalyst. The company has no marketed products and funds operations entirely through public equity raises. In February 2024, the U.S. Food and Drug Administration lifted a clinical hold that had paused the nomlabofusp program for more than two years, clearing the path for a pivotal trial design that could support accelerated approval. Larimar manufactures drug substance at a contract facility in the United States and runs clinical sites across North America and Europe, with a particular concentration in Friedreich's ataxia patient registries in the northeastern United States and Italy. The firm maintains a lean operational footprint, with fewer than 100 employees and a corporate headquarters in Bala Cynwyd, Pennsylvania, a Philadelphia suburb. Larimar does not operate adjacent venture arms, philanthropic foundations, or co-investment vehicles; it is a pure-play rare-disease developer. February 2024: The FDA lifted a full clinical hold on the nomlabofusp program, allowing the firm to resume dosing in its ongoing Phase 2 dose-exploration study and initiate discussions on an accelerated approval pathway (per the firm, February 2024). Larimar's structural differentiator is an unusual degree of corporate mortality married to a single-molecule survival instinct. After the original Zafgen therapeutic failed in a pivotal obesity trial — linked to patient deaths — the company could have dissolved. Instead, it reverse-merged with a preclinical rare-disease startup, abandoned metabolic disease, and bet the entire remaining enterprise on a protein-engineering thesis that had never entered human trials. That transactional pivot is the architecture of the current company: a publicly listed shell that acquired a science project and kept it alive through a clinical hold long enough to reach the FDA negotiating table.
General information
Firm type
Asset Manager
Year founded
2005
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Bala Cynwyd
Corporate office
Bala Cynwyd, PA, United States
Principals
Carole Ben-Maimon
President and Chief Executive Officer
Sector focus
Frequently asked questions
Who runs Larimar Therapeutics' clinical and corporate strategy?
Carole Ben-Maimon serves as President and Chief Executive Officer and has led the company through its pivot from metabolic disease to rare neurological disorders. She previously ran global pharmaceuticals at Impax Laboratories and spent over two decades in the generics and specialty pharmaceutical industry before joining the rare-disease biotech. Her leadership team includes Dr. Rusty Clayton as Chief Medical Officer, who oversees the nomlabofusp clinical program (public record).
How did Larimar end up focused on Friedreich's ataxia after originally being an obesity company?
The original entity, Zafgen, developed a methionine aminopeptidase 2 inhibitor for obesity that was abandoned after patient deaths in a pivotal trial. In 2020, Zafgen reverse-merged with Chondrial Therapeutics, a private biotech founded specifically to develop protein replacement therapies for mitochondrial disease. The combined company, renamed Larimar, discarded all existing metabolic programs and concentrated its balance sheet on Chondrial's lead candidate, now called nomlabofusp (per the firm, 2020).
What is the status of nomlabofusp with the FDA?
As of February 2024, the FDA lifted a full clinical hold that had been in place since 2021, after reviewing preclinical data intended to address safety questions. The hold had paused dosing in Larimar's Phase 2 dose-exploration study. With the hold resolved, the company is progressing the trial and engaging with the FDA on an accelerated approval pathway, which could potentially allow for a Biologics License Application submission based on existing Phase 2 data plus an ongoing confirmatory study (per the firm, February 2024).
Does Larimar have any approved products or other pipeline programs?
Larimar has no marketed products. The entire pipeline is built around the single fusion-protein platform that produced nomlabofusp; additional undisclosed discovery-stage programs exist but have not been clinically validated. The firm's near-term survival hinges entirely on nomlabofusp's performance in Friedreich's ataxia trials and any resulting regulatory approval.
How does Larimar fund its operations?
Larimar is publicly traded on Nasdaq under the ticker LRMR and funds all research, clinical operations, and overhead through equity financings in the public markets. The firm has raised capital via multiple follow-on offerings since the 2020 merger, including a public offering in 2023 that brought net proceeds of roughly $100 million. It does not receive revenue from product sales or partnerships (per SEC filings, 2023).
What is Friedreich's ataxia and how does nomlabofusp address it?
Friedreich's ataxia is a rare, inherited neurodegenerative disease caused by a deficiency of the mitochondrial protein frataxin. Patients experience progressive loss of coordination, muscle weakness, and often fatal cardiac complications. Nomlabofusp is a recombinant fusion protein designed to cross cell membranes, enter mitochondria, and deliver functional frataxin — effectively replacing the missing protein rather than correcting the underlying genetic defect. The therapy is administered by subcutaneous injection.
Where are Larimar's clinical trials being conducted?
Larimar's Phase 2 dose-exploration trial and planned registrational program run sites across the United States and in several European countries, including Italy, which has a comparatively high concentration of Friedreich's ataxia patients. Manufacturing occurs at a U.S. contract development and manufacturing organization, a common structure for clinical-stage firms without in-house production capacity.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: